scholarly journals Protective immunity against equine herpesvirus type 1 is associated with antibody responses to the vaccine candidate Ab4ΔORF2

2021 ◽  
Vol 53 (S56) ◽  
pp. 53-54
Keyword(s):  
Protective Immunity ◽  
Vaccine Candidate ◽  
Antibody Responses ◽  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

scholarly journals An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease

2019 ◽  
Vol 93 (22) ◽  
Author(s):  
Christiane L. Schnabel ◽  
Susanna Babasyan ◽  
Alicia Rollins ◽  
Heather Freer ◽  
Christine L. Wimer ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Challenge Infection ◽  
Equine Herpesvirus ◽  
Virus Shedding ◽  
Reading Frame ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1 ◽  
Open Reading Frame 2

ABSTRACT Equine herpesvirus type 1 (EHV-1) outbreaks continue to occur despite widely used vaccination. Therefore, development of EHV-1 vaccines providing improved immunity and protection is ongoing. Here, an open reading frame 2 deletion mutant of the neuropathogenic EHV-1 strain Ab4 (Ab4ΔORF2) was tested as a vaccine candidate. Three groups of horses (n = 8 each) were infected intranasally with Ab4ΔORF2 or the parent Ab4 virus or were kept as noninfected controls. Horses infected with Ab4ΔORF2 had reduced fever and nasal virus shedding compared to those infected with Ab4 but mounted similar adaptive immunity dominated by antibody responses. Nine months after the initial infection, all horses were challenged intranasally with Ab4. Previously noninfected horses (control/Ab4) displayed clinical signs, shed large amounts of virus, and developed cell-associated viremia. In contrast, 5/8 or 3/8 horses previously infected with Ab4ΔORF2 or Ab4, respectively, were fully protected from challenge infection as indicated by the absence of fever, clinical disease, nasal virus shedding, and viremia. All of these outcomes were significantly reduced in the remaining, partially protected 3/8 (Ab4ΔORF2/Ab4) and 5/8 (Ab4/Ab4) horses. Protected horses had EHV-1-specific IgG4/7 antibodies prior to challenge infection, and intranasal antibodies increased rapidly postchallenge. Intranasal inflammatory markers were not detectable in protected horses but quickly increased in control/Ab4 horses during the first week after infection. Overall, our data suggest that preexisting nasal IgG4/7 antibodies neutralize EHV-1, prevent viral entry, and thereby protect from disease, viral shedding, and cell-associated viremia. In conclusion, improved protection from challenge infection emphasizes further evaluation of Ab4ΔORF2 as a vaccine candidate. IMPORTANCE Nasal equine herpesvirus type 1 (EHV-1) shedding is essential for virus transmission during outbreaks. Cell-associated viremia is a prerequisite for the most severe disease outcomes, abortion and equine herpesvirus myeloencephalopathy (EHM). Thus, protection from viremia is considered essential for preventing EHM. Ab4ΔORF2 vaccination prevented EHV-1 challenge virus replication in the upper respiratory tract in fully protected horses. Consequently, these neither shed virus nor developed cell-associated viremia. Protection from virus shedding and viremia during challenge infection in combination with reduced virulence at the time of vaccination emphasizes ORF2 deletion as a promising modification for generating an improved EHV-1 vaccine. During this challenge infection, full protection was linked to preexisting local and systemic EHV-1-specific antibodies combined with rapidly increasing intranasal IgG4/7 antibodies and lack of nasal type I interferon and chemokine induction. These host immune parameters may constitute markers of protection against EHV-1 and be utilized as indicators for improved vaccine development and informed vaccination strategies.

scholarly journals Neonatal Immunization with a Single IL-4/Antigen Dose Induces Increased Antibody Responses after Challenge Infection with Equine Herpesvirus Type 1 (EHV-1) at Weanling Age

PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0169072 ◽  
Author(s):  
Bettina Wagner ◽  
Gillian Perkins ◽  
Susanna Babasyan ◽  
Heather Freer ◽  
Alison Keggan ◽  
...  
Keyword(s):  
Challenge Infection ◽  
Antibody Responses ◽  
Equine Herpesvirus ◽  
Antigen Dose ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD

1998 ◽  
Vol 56 (1) ◽  
pp. 11-24 ◽  
Author(s):  
Yunfei Zhang ◽  
Patrick M Smith ◽  
E.Bart Tarbet ◽  
Nikolaus Osterrieder ◽  
Stephen R Jennings ◽  
...  
Keyword(s):  
Protective Immunity ◽  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

Biochemical transformation of deoxythymidine kinase-deficient mouse cells with UV-irradiated equine herpesvirus type 1.

1978 ◽  
Vol 28 (1) ◽  
pp. 361-367 ◽  
Author(s):  
G P Allen ◽  
J J McGowan ◽  
G A Gentry ◽  
C C Randall
Keyword(s):  
Equine Herpesvirus ◽  
Deficient Mouse ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1 ◽  
Mouse Cells

Decreased virus-neutralizing antibodies against equine herpesvirus type 1 in nasal secretions of horses after 12-hour transportation

2021 ◽  
pp. 103665
Author(s):  
Hiroshi Bannai ◽  
Yuji Takahashi ◽  
Hajime Ohmura ◽  
Yusaku Ebisuda ◽  
Kazutaka Mukai ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1 ◽  
Nasal Secretions

scholarly journals Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza

Vaccine ◽  
2008 ◽  
Vol 26 (19) ◽  
pp. 2335-2343 ◽  
Author(s):  
Cristina Rosas ◽  
Gerlinde R. Van de Walle ◽  
Stephan M. Metzger ◽  
Karin Hoelzer ◽  
Edward J. Dubovi ◽  
...  
Keyword(s):  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1 ◽  
Canine Influenza

A touchdown PCR for the differentiation of equine herpesvirus type 1 (EHV-1) field strains from the modified live vaccine strain RacH

1994 ◽  
Vol 50 (1-3) ◽  
pp. 129-136 ◽  
Author(s):  
Nikolaus Osterrieder ◽  
Peter H. Hübert ◽  
Christine Brandmüller ◽  
Oskar-Rüger Kaaden
Keyword(s):  
Vaccine Strain ◽  
Live Vaccine ◽  
Live Vaccine Strain ◽  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1 ◽  
Touchdown Pcr ◽  
Modified Live Vaccine

Late-Term Abortion, Stillbirth, and Neonatal Foal Death in Kyrgyzstan: First Isolation of Equine Herpesvirus Type 1 in the Country

2017 ◽  
Vol 51 ◽  
pp. 46-53
Author(s):  
Maksat Akhmedzhanov ◽  
Rysbek Nurgaziev ◽  
Jailobek Orozov ◽  
Irmgard Moser ◽  
Nikolaus Osterrieder ◽  
...  
Keyword(s):  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

Recombinant Glycoprotein B of Equine herpesvirus Type 1 Elicits Protective Immune Response against Challenge in BALB/c Mouse Model

2021 ◽  
Author(s):  
Alok Joshi ◽  
R.P. Gupta ◽  
Selvaraj Pavulraj ◽  
Bidhan Chandra Bera ◽  
Taruna Anand ◽  
...  
Keyword(s):  
Immune Response ◽  
Plasmid Dna ◽  
Protective Immune Response ◽  
Glycoprotein B ◽  
Equine Herpesvirus ◽  
Recombinant Glycoprotein ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1

Background: Equine herpesvirus type 1 (EHV-1) is the most important viral pathogen of equines, causing respiratory illness, abortion, neonatal foal mortality and neurologic disorders. Large numbers of commercial EHV-1 vaccines are available to protect equines from the disease, but they provide only partial protection. Despite immunization with inactivated and modified live virus vaccine, mares show abortions. Present study was aimed to investigate the immunogenicity and protective efficacy of EHV-1 recombinant glycoprotein B (rgB) and gB expressing plasmid DNA against EHV-1 infection in BALB/c mice model.Methods: About 3-4 weeks old 225 female BALB/c mice were selected for the comparative study of immunization followed by challenged with EHV-1/India/Tohana/96-2 strain virus in 5 different groups of 45 animals each.Result: Following immunization, rgB vaccinated mice showed optimal stimulation of EHV-1 gB specific cell mediated and humoral mediated immunity (HMI and CMI). The gB expressing plasmid DNA vaccinated mice developed only CMI while inactivated whole virus vaccinated mice had only HMI. Upon EHV-1 challenge, all infected mice displayed variable levels of clinical signs with changes in body weight, however, vaccinated mice showed very rapid recovery with optimal protection. Positive control group mice showed severe pulmonary lesions along with persistence virus infection till 5 days post challenge (dpc) whereas vaccinated mice had less pulmonary lesion only up to 3dpc. Minimal lung lesions and early virus clearance was observed in the rgB immunized mice in comparison to the gB plasmid DNA and inactivated EHV-1 vaccine immunized mice. It has been concluded that immunization with rgB elicits optimum protective immune response against EHV-1 infection in mice model. The rgB could be a potential vaccine candidate against EHV-1 infection in equine in the future.

scholarly journals A retrospective study on equine herpesvirus type-1 associated myeloencephalopathy in France (2008–2011)

2015 ◽  
Vol 179 (3-4) ◽  
pp. 304-309 ◽  
Author(s):  
Gaby van Galen ◽  
Agnes Leblond ◽  
Pierre Tritz ◽  
Ludovic Martinelle ◽  
Stéphane Pronost ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Equine Herpesvirus ◽  
Herpesvirus Type ◽  
Equine Herpesvirus Type ◽  
Equine Herpesvirus Type 1
Sign in / Sign up

Export Citation Format

Share Document